Moving Forward: What’s Next?
June 24 – 25, 2014

Goal: Understand Cost and Quality to Move Toward Value
Day 1 Roundtable Feedback

Where is HCT quality measurement today?

- HCT was a leader in outcomes tracking and quality, but is in danger of falling behind
- We may be able to learn from other specialties
  - Sharing best practices; variation measurement
  - Center-specific long-term survival outcomes
- Needs to be more action-oriented
  - Slowed by retrospective focus
  - More actionable data needed
### Areas of Measurement Interest

<table>
<thead>
<tr>
<th>Disease</th>
<th>Care Teams</th>
<th>Outcomes</th>
<th>Transplant Episode</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume of each type</td>
<td>Qualifications &amp; Ratios</td>
<td>GVHD, Infections</td>
<td>LOS</td>
</tr>
<tr>
<td>Specialties of each center</td>
<td>Level/Type</td>
<td>QOL; Return to Work</td>
<td></td>
</tr>
<tr>
<td>Survival by category</td>
<td>Care Coordination</td>
<td>Relapse Rate</td>
<td>Readmission rate in first 100 days</td>
</tr>
</tbody>
</table>

### Measurement Concerns

- Other areas of cancer largely use process/operational measures.
- SCT is therapy focused; other specialties are condition/disease focused.
- Could decrease patient access.
- Complications and patient mix hard to capture.
- Many things out of transplant center control.
- Care is uniformly good; differences are mainly in treatment of high-risk or rare disease patients.
What Else Matters?

- Team Performance; Multi-disciplinary integration
- Long-term Follow-up
- Symptom Management; Palliative Care
- Relationship with referral network
- Alignment with best practices, care pathways
- Physician compensation models

Day 2 Roundtable: Performance-Based Reimbursement
## Roundtable Feedback

- Strong alignment around patient outcomes
  - Need alignment from payers on what matters
  - Is the real issue quality or resource-use?

- Moving beyond case-rate at this point is difficult, but
  - Maturity of this field’s use of case-rate opens up options
  - Broader integration with oncology programs for reimbursement and quality evaluation

- Opportunities to work collaboratively will be crucial
  - Engage with NQF?

- More attention to patient perspective needed

## Community Roles

- ASBMT = professional society
- CIBMTR = scientific research registry
- FACT = voluntary accreditation
- NMDP = donor cells

Payers want quality and value, but define quality differently

- Who is responsible for measuring quality?
- Who is responsible for disseminating information
- Are they same?